DeepMed Research

YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

Phase 1

Terminated

Conditions: Advanced Solid Cancers

Interventions: Drug: Rapamune
Drug: Abraxane

First Posted Date: 2006-06-15

Last Posted Date: 2014-01-14

Lead Sponsor: Yale University

Target Recruit Count: 23

Registration Number: NCT00337376

Locations: 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States

Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Liver Cancer

Interventions: Biological: bevacizumab
Drug: chemotherapy
Drug: embolization therapy
Procedure: hepatic artery infusion

First Posted Date: 2006-06-12

Last Posted Date: 2021-08-13

Lead Sponsor: Yale University

Target Recruit Count: 26

Registration Number: NCT00335829

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Nicotinic Receptor Augmentation of SSRI Antidepressants

Phase 2

Completed

Conditions: Depressive Disorder

First Posted Date: 2006-04-27

Last Posted Date: 2007-04-19

Lead Sponsor: Yale University

Target Recruit Count: 60

Registration Number: NCT00319319

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

Relational Parenting Group for Opioid-addicted Mothers

Phase 2

Completed

Conditions: Child Abuse
Substance Abuse

First Posted Date: 2006-04-27

Last Posted Date: 2020-03-31

Lead Sponsor: Yale University

Target Recruit Count: 120

Registration Number: NCT00319241

Locations: 🇺🇸
The APT Foundation, New Haven, Connecticut, United States

Stage I Randomized Trial of Mentalization-Based Therapy for Substance Using Mothers of Infants and Toddlers

Not Applicable

Completed

Conditions: Child Abuse and Neglect
Maternal Substance Use

Interventions: Behavioral: Mentalizing Therapy for Substance Using Mothers
Behavioral: Standard Parent Education for Substance Using Mothers

First Posted Date: 2006-04-27

Last Posted Date: 2020-04-09

Lead Sponsor: Yale University

Target Recruit Count: 47

Registration Number: NCT00319436

Locations: 🇺🇸
The APT Foundation, New Haven, Connecticut, United States

Buprenorphine and Integrated HIV Care

Phase 4

Completed

Conditions: AIDS
HIV Infections
Drug Addiction
Substance-related Disorders
Human Immunodeficiency Virus

Interventions: Behavioral: Counseling
Other: Physician Management

First Posted Date: 2006-04-24

Last Posted Date: 2020-04-03

Lead Sponsor: Yale University

Target Recruit Count: 52

Registration Number: NCT00317460

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Specialized Treatment Early in Psychosis (STEP)

Not Applicable

Completed

Conditions: Schizophrenia and Disorders With Psychotic Features

Interventions: Behavioral: Cognitive Behavioral Group Therapy
Other: Treatment as Usual in the community
Behavioral: Cognitive remediation
Drug: Medications
Behavioral: MFG
Behavioral: Assertive case management

First Posted Date: 2006-03-31

Last Posted Date: 2017-02-08

Lead Sponsor: Yale University

Target Recruit Count: 120

Registration Number: NCT00309452

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

Transcranial Magnetic Stimulation for "Voices"

Phase 2

Completed

Conditions: Hallucinations
Schizophrenia

Interventions: Device: Active 1-Hertz Repetitive transcranial magnetic stimulation
Device: 1-hertz Repetitive Transcranial Magnetic Stimulation

First Posted Date: 2006-03-30

Last Posted Date: 2020-04-02

Lead Sponsor: Yale University

Target Recruit Count: 85

Registration Number: NCT00308997

Locations: 🇺🇸
Yale Psychiatric Research, New Haven, Connecticut, United States

Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Phase 1

Terminated

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: docetaxel
Other: placebo
Drug: idronoxil

First Posted Date: 2006-03-17

Last Posted Date: 2018-01-17

Lead Sponsor: Yale University

Target Recruit Count: 31

Registration Number: NCT00303888

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

Tele-HF: Yale Heart Failure Telemonitoring Study

Not Applicable

Completed

Conditions: Congestive Heart Failure

Interventions: Other: Telemonitoring

First Posted Date: 2006-03-15

Last Posted Date: 2020-03-30

Lead Sponsor: Yale University

Target Recruit Count: 1660

Registration Number: NCT00303212

Locations: 🇺🇸
Morehouse School of Medicine/Cardiology, Atlanta, Georgia, United States
🇺🇸
Heart Clinic of Louisiana, Marrero, Louisiana, United States
🇺🇸
Cardiology Specialists, Ltd., Westerly, Rhode Island, United States

and more 30 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy